Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models.

Journal Article (Journal Article;Review)

Age-related macular degeneration (AMD) is a major leading cause of irreversible visual impairment in the world with limited therapeutic interventions. Histological, biochemical, genetic, and epidemiological studies strongly implicate dysregulated lipid metabolism in the retinal pigmented epithelium (RPE) in AMD pathobiology. However, effective therapies targeting lipid metabolism still need to be identified and developed for this blinding disease. To test lipid metabolism-targeting therapies, preclinical AMD mouse models are needed to establish therapeutic efficacy and the role of lipid metabolism in the development of AMD-like pathology. In this review, we provide a comprehensive overview of current AMD mouse models available to researchers that could be used to provide preclinical evidence supporting therapies targeting lipid metabolism for AMD. Based on previous studies of AMD mouse models, we discuss strategies to modulate lipid metabolism as well as examples of studies evaluating lipid-targeting therapeutics to restore lipid processing in the RPE. The use of AMD mouse models may lead to worthy lipid-targeting candidate therapies for clinical trials to prevent the blindness caused by AMD.

Full Text

Duke Authors

Cited Authors

  • Landowski, M; Bowes Rickman, C

Published Date

  • 2022

Published In

Volume / Issue

  • 38 / 1

Start / End Page

  • 3 - 32

PubMed ID

  • 34788573

Pubmed Central ID

  • PMC8817708

Electronic International Standard Serial Number (EISSN)

  • 1557-7732

Digital Object Identifier (DOI)

  • 10.1089/jop.2021.0067


  • eng

Conference Location

  • United States